StudyReasons for exclusion
Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. [Review] [33 refs]. Am J Med. 43; 121(1):43–49.Review
Tisdale JE. Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. [Review] [47 refs]. Am J Health Syst Pharm. 1998; 55(Suppl 1):8–16.Review
Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.[see comment][erratum appears in BMJ 1998 Jun 6;316(7146):1733]. [Review] [124 refs]. BMJ. 1998; 316(7140):1303–1309.Guideline
Berglund U, Lassvik C, Wallentin L. Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J. 1987; 8(1):25–30.Follow-up 8 weeks
Khurmi NS, Bowles MJ, Raftery EB. Are anti- platelet drugs of value in the management of patients with chronic stable angina? A study with ticlopidine. Clin Cardiol. 1986; 9(10):493–498.Follow-up 4 weeks
Berglund U, von SH, Wallentin L. Effects of ticlopidine of platelet function in men with stable angina pectoris. Thrombosis & Haemostasis. 1985; 54(4):808–812.Outcome not relevant (platelet aggregation)
Miwa K, Kambara H, Kawai C. Exercise-induced angina provoked by aspirin administration in patients with variant angina. Am J Cardiol. 1981; 47(6):1210–1214.N=8
Passamani ER. Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease. Circulation. 1980; 62(6:Pt 2):V106–V110.Review
Davis JW, Lewis HD, Jr., Phillips PE et al. Effect of aspirin on exercise-induced angina. Clinical Pharmacology & Therapeutics. 1978; 23(5):505–510.N=13
Frishman WH, Christodoulou J, Weksler B et al. Aspirin therapy in angina pectoris: effects on platelet aggregation, exercise tolerance, and electrocardiographic manifestations of ischemia. Am Heart J. 1976; 92(1):3–10.N=11
Baigent C, Sudlow C, Collins R et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002; 324(7329):71–86.Review -relevant references noted
Bouvy ML, Heerdink ER, Klungel OH et al. Women with angina pectoris receive less antiplatelet treatment than men. Br J Gen Pract. 1999; 49(441):299–300.Outcomes not relevant (no of patients treated with antiplatelet)
Burgstahler C, Geisler T, Lindemann S et al. Elevated coronary calcium scores are associated with higher residual platelet aggregation after clopidogrel treatment in patients with stable angina pectoris. Int J Cardiol. 2009; 135(1):132–135.Outcome not relevant (platelet aggregation)
Khan H, Jan H, Hafizullah M. Study on clopidogrel in inhibition of platelet aggregation in suspected angina patients, treated with a daily dose of 75 mg of clopidogrel for 7 days. Iranian Journal of Pharmaceutical Research. 2009; 8(2):135–140.Outcome not relevant (platelet aggregation)
Saha S, Berglund M, Sylven C et al. Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. Int J Cardiol. 2008; 123(2):-196.Outcome not relevant (platelet aggregation)
Winther K, Husted SE, Vissinger H. Low dose acetylsalicylic acid in the antithrombotic treatment of patients with stable angina pectoris and acute coronary syndromes (unstable angina pectoris and acute myocardial infarction). Pharmacol Toxicol. 1994; 74(3):141–147.Review
Sullivan J, Amarshi N. Dual antiplatelet therapy with clopidogrel and aspirin. Am J Health Syst Pharm. 2008; 65(12):1134–1143.Review
Knight CJ. Antiplatelet treatment in stable coronary artery disease. [Review] [16 refs]. Heart. 2003; 89(10):1273–1278.Review
Ruzyllo W, Ponikowski P, Wilkins A et al. Clinical characteristics and methods of treatment of patients with stable coronary heart disease in the primary care settings--the results of the Polish, Multicentre Angina Treatment Pattern (ATP) study. Int J Clin Pract. 2004; 58(12):1127–1133.Survey
Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29(1):21–30.Outcomes not relevant (platelet aggregation)
Widimsky P, Motovska Z, Simek S et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.[see comment]. Eur Heart J. 2008; 29(12):1495–1503.Patients undergoing elective coronary angiography
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994; 308(6921):81–106.Review
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038):1329–1339.No stable angina patients
Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001; 357(9253):373–380.Review
Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996; 348(9039):1413–1416.Patient population not relevant (patients with upper GI bleeding)
Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta- analysis. BMJ. 2000; 321(7270):1183–1187.Outcome not relevant (gastro intestinal haemorrhage)
Sbar S, Schlant RC. Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. Journal of the American Medical Association. 1967; 201(11):865–867.dipyridamole
Anon. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. Journal of the American Medical Association. 1980; 243(7):661–669.33% of patients with angina
Chen WH, Cheng X, Lee PY et al. Aspirin Resistance and Adverse Clinical Events in Patients with Coronary Artery Disease. Am J Med. 2007; 120(7):631–635.% of stable angina patients not reported.
Becker MC. Angina pectoris: a double blind study with dipyridamole. Journal of the Newark Beth Israel Hospital. 1967; 18:88–94.Dipyridamole
Chesebro JH, Webster MW, Smith HC et al. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation. Circulation. 1989; 80(Suppl 2):266.Abstract
Wirecki M. Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis. 1967; 20(3):139–145.Dipyridamole
Manson JE, Grobbee DE, Stampfer MJ et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med. 1990; 89(6):772–776.Sub group analysis of the study – patients with chronic stable angina included in the review (Ref ID 392)

From: Appendix E, Included – Excluded Studies and Clinical Evidence Tables

Cover of Stable Angina
Stable Angina: Methods, Evidence & Guidance [Internet].
NICE Clinical Guidelines, No. 126.
National Clinical Guidelines Centre (UK).
Copyright © 2011, National Clinical Guidelines Centre.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of the National Clinical Guidelines Centre to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.